Development of an efficient, robust MS-based platform for early detection of acute kidney injury

急性肾损伤（AKI）是住院患者的严重并发症，是危及生命的并发症，死亡率仍然很高。此外，AKI与强化和长期治疗的高费用有关。到目前为止，还不可能早期发现AKI。然而，早期发现对于开始适当的治疗至关重要，从而预防疾病的发展，或至少降低严重程度。这种方法会降低死亡率，也会降低成本。该提案旨在开发一种技术平台，基于尿液中的特定蛋白质和肽，即所谓的生物标志物，能够早期检测AKI。这些生物标记物已经被确定。为了有效的临床应用，必须开发一个能够进行准确和快速分析的平台，这是该项目的范围。在成功完成该项目后，将有一种强大的技术可以早期发现AKI，从而开始适当的早期治疗措施。我们预计，由于这个项目，由于AKI的死亡率可以显著降低，并可以降低成本。

Acute Kidney Injury (AKI) as a severe complication in hospitalized patients, a life-threatening complication that still has a high mortality. In addition, AKI is associated with high costs for intensive and prolongued treatment. To date, no early detection of AKI is possible. However, early detection is essential to initiate appropriate treatment, thereby preventing development of disease, or at least reducing the severity. Such an appproach would reduce mortality, and also costs. The proposal aims at developing a technology platform that enables early detection of AKI, based on specific proteins an peptides in urine, so-called biomarkers. These biomarkers have already been identified. For their efficient clinical application a plattform that allows accurate and fast analysis has to be developed, this development is the scope of the project. Upon successful completion of the project, a robust technology will be available that enables early detection of AKI, hence initiation of appropriate early therapeutic measures. We anticipate that as a result of this project, mortality due to AKI can be significantly decreased, and costs can be reduced.